Acute coronary syndrome treatment market to more than triple by 2023

30 July 2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary syndrome (ACS) treatment market to more than triple in value, from $12.3 billion in 2013 to $43.4 billion by 2023.

According to research and consulting firm GlobalData’s latest report, across seven major markets (the USA, France, Germany, Italy, Spain, the UK and Japan) there are three monoclonal antibodies (MAbs), all PCSK9 inhibitors, with the potential to reshape the post-ACS, dyslipidemia landscape.

Amgen’s (Nasdaq: AMGN) evolocumab, Sanofi (Euronext: SAN) and Regeneron’s (Nasdaq: REGN) alirocumab, and Pfizer’s (NYSE: PFE) bococizumab are all demonstrating safe and significant reductions of serum LDL-C levels in major clinical trials, and GlobalData expects these treatments to be launched in the middle of the forecast period.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK